Table 1: VL case management: patient experiences.
IndiaNepalBangladeshOverall
20092010200920102009201020092010
No. of new VL cases detected638820212139241
No. of VL cases started with (%)
  (i) SAG34/63
(54%)		1/8
(13%)		0/8
(0%)		0/20
(0%)		8/8
(100%)		0/13
(0%)		42/79
(53%)		1/41
(2%)
  (ii) Amphotericin B6/63
(10%)		0/8
(0%)		5/8
(63%)		16/20
(80%)		0/8
(0%)		0/13
(0%)		11/79
(14%)		16/41
(39%)
  (iii) Miltefosine23/63
(37%)		7/8
(88%)		3/8
(38%)		4/20
(20%)		0/8
(0%)		13/13
(100%)		26/79
(33%)		24/41
(59%)
No. of VL cases given correct dosage schedule (%)62/63
(98%)		8/8
(100%)		3/3
(100%)		20/20
(100%)		8/8
(100%)		13/13
(100%)		73/74
(99%)		41/41
(100%)
No. of VL cases with treatment interrupted (%)1/63
(2%)		1/8
(13%)
(side effect)		0/3
(0%)		1/20
(5%)
(no drug)		0/8
(0%)		0/13
(0%)		1/74
(1%)		2/41
(5%)
No. VL cases experiencing side effects (%)2/63
(3%)		1/8
(13%)		0/3
(0%)		1/20
(5%)		0/8
(0%)		2/13
(15%)		2/74
(3%)		4/41
(10%)
No. VL cases received doctor’s advice on (%)
  (i) Need to comply with treatment (%)63/63
(100%)		8/8
(100%)		3/3
(100%)		20/20
(100%)		—313/13
(100%)		66/66
(100%)		41/41
(100%)
  (ii) Side effects (%)2/63
(3%)		8/8
(100%)		3/3
(100%)		6/20
(30%)		—212/13
(92%)		5/66
(8%)		26/41
(63%)
  (iii) Compliance with follow up (%)37/63
(59%)		8/8
(100%)		3/3
(100%)		11/20
(55%)		—212/13
(92%)		40/66
(61%)		31/41
(76%)
Did you comply with FU advise37/63
(59%)		8/8
(100%)		3/3
(100%)		7/20
(35%)		—212/13
(92%)		40/66
(61%)		27/41
(66%)
Volunteer support for home treatment with Miltefosine (%)15/23
(65%)		4/7
(57%)		3/3
(100%)		3/4
(75%)		NA44/13
(31%)		18/26
(69%)		11/24
(46%)
213 patients were diagnosed as relapse of VL and referred to district hospital. Treatment status could not be ascertained subsequently.
3Information on doctor advice to patients is not captured in Bangladesh in the interview for patients who received other than Miltefosine treatment.
4Not applicable as no patient received Miltefosine.